Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New dashboard aims to cut pain for tiniest patients

NCT ID NCT07629661

Symptom relief Sponsor: Erasmus Medical Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a computer dashboard that helps doctors and nurses in the Neonatal Intensive Care Unit (NICU) manage pain in newborn babies. The dashboard shows real-time data to flag when a baby may be in discomfort. Researchers will compare pain levels in 1,250 babies before and after the dashboard is introduced, and also ask staff about how well it works.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
clinical pain management dashboard (software device)
What this could lead to
If successful, this dashboard could help NICU teams spot and treat pain in newborns more quickly, reducing suffering.
What could go wrong
This is a single-center study with a before-and-after design, so results may not apply to other hospitals. The dashboard is a decision-support tool, not a treatment, so its impact depends on how staff use it.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,250 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

Children (under 18), adults (18 to 64) and older adults (65 and over)

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Primary endpoint - Effectiveness evaluation (neonates): * Admitted to the NICU of Erasmus MC-Sophia Children's Hospital during either the pre-implementation or post-implementation phase * Admitted and discharged during the respective phase * Parental consent for use of medical information provided upon admission Secondary endpoints - Implementation process evaluation (healthcare professionals): * Physician, nurse, or nurse specialist working in the NICU during the study period who has been exposed to TMD-C * Management staff who has been exposed to TMD-C Secondary endpoints - Implementation process evaluation (parents): \- Parent or guardian of an included neonate who was exposed to the dashboard during the samenzorgvisite (family-integrated ward round) Primary endpoint - Effectiveness evaluation (neonates): * Readmitted to the NICU during the same study phase * Admitted to the NICU for less than 24 hours * Discharged or transferred before 7 days of admission without complete pain management data available Secondary endpoints - Implementation process evaluation: \- None

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Decision support systems, clinical are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

agnosia Pain

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Decision support systems, clinical Implementation research Neonatal intensive care Pain assessment Pain management

Contacts and locations

Locations

  • Erasmus MC-Sophia Children's hospital

    Rotterdam, Netherlands

More trials for these conditions

Other studies related to the condition(s) this trial covers.